Ardelyx’s kidney disease drug reduces elevated phosphate levels in late-stage study
(Reuters) – Ardelyx Inc said on Tuesday its experimental drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease (CKD) in a late-stage study. The treatment, tenapanor, showed a greater difference in serum phosphorus levels compared to placebo, the company said. Elevated phosphorus levels are common in CKD patients, especially those… Read More »